Skip to content

The Predictive Value of Transcutaneous VNS for Effect of an Implanted VNS System in Epilepsy Patients

The Predictive Value of Transcutaneous VNS for Effect of an Implanted VNS System in Epilepsy Patients - Predictive Value of tVNS in Epilepsy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON42025
Enrollment
15
Registered
2015-05-08
Start date
2015-08-25
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurologische aandoeningen, hersenaandoeningen, epilepsie epilepsy epileptic seizure

Interventions

Included patients will use tVNS for three months prior to implantation of a VNS system.
epilepsy

Sponsors

Medisch Spectrum Twente
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Age >= 18 years Diagnosed with epilepsy Stable epilepsy Scheduled for an implantable VNS system Able to read and understand Dutch Physically and cognitively capable of using the tVNS device and participating in the measurements

Exclusion criteria

Exclusion criteria: severe cognitive impairment(s)

Design outcomes

Primary

MeasureTime frame
The predictive value of tVNS for the effects of the implantable VNS system. Positive effects of the VNS system are seizure frequency reduction, seizure intensity reduction, seizure duration reduction (obtained from patient*s seizure diary (NHS3 clinician rated scale)) and improvement in quality of life (QOLIE 31P) or mood (MADRS). Correlations between these effects and effects of tVNS will be evaluated.

Secondary

MeasureTime frame
The effects of 6 weeks and 3 months of tVNS and the effects of 3, 6, 9 and 12 months of implanted VNS will be evaluated by measuring a broad set of parameters as described in the protocol (Chapter 3).

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)